U.S., March 21 -- ClinicalTrials.gov registry received information related to the study (NCT07485504) titled 'Safety and Efficacy of DIT101 in Relapsed or Refractory Hematologic Malignancies' on March 02.
Brief Summary: This study is a single-arm, open-label clinical trial designed to evaluate the safety and tolerability of DIT101 in adults with relapsed or refractory hematologic malignancies and to explore its potential anti-tumor effects.
DIT101 is an investigational in vivo CAR-T cell therapy administered by intravenous infusion. After administration, it is intended to generate CAR-T cells within the patient's body that can recognize and attack tumor cells. Unlike approved autologous CAR-T therapies, DIT101 does not require collection ...